Three months after a Complete Response Letter stopped GTx-104 at the finish line, Grace Therapeutics now has FDA meeting minutes in hand from a Type A meeting held to map the exact path back. That distinction matters: Type A meetings are reserved for resolving disputes or addressing critical issues that would otherwise stall development entirely, and receiving formal minutes signals the agency has committed its guidance to writing. For a program this close to approval, that written record is the operational blueprint Grace needed.
The April 23, 2026 CRL cited deficiencies that were procedural rather than clinical: outstanding Chemistry, Manufacturing, and Controls items including leachables data for product packaging, additional CMC time points, cGMP compliance concerns at the contract manufacturing organization, and non-clinical toxicology risk assessments. Nothing in that list touched efficacy or the Phase 3 clinical dataset itself. That separation is important. The agency did not challenge whether GTx-104’s intravenous nimodipine formulation works; it challenged whether Grace could consistently manufacture and package it to specification. Resolving CMC and non-clinical gaps, while not trivial, follows a more predictable regulatory playbook than addressing a clinical signal problem would.
The clinical case for GTx-104 remains intact. Aneurysmal subarachnoid hemorrhage is a neurological emergency where consistent drug delivery is genuinely difficult: oral nimodipine carries roughly 7% bioavailability and high plasma variability, and critically ill patients in neuro-ICU settings often cannot reliably absorb oral medications at all. GTx-104’s nanoparticle IV formulation targets 100% bioavailability with predictable concentrations, which is the pharmacokinetic argument that drove FDA engagement this far in the first place. The Type A meeting outcome and the updated corporate presentation Grace filed July 28 both suggest the company has a defined resubmission package taking shape, not an open-ended remediation effort.
The single marker to track from here is the NDA resubmission class designation. A Class 1 resubmission carries a two-month review clock; Class 2 carries six months. Given that the outstanding deficiencies are CMC and non-clinical rather than clinical, Grace’s ability to argue for a Class 1 filing will determine whether approval arrives in 2026 or slips into mid-2027.
Source link: https://www.sec.gov/Archives/edgar/data/1444192/000114036126029837/ef20078866_8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
